Auctus-backed PharmaLex buys Regulis Consulting

The acquisition was financed via equity from Auctus and PharmaLex's management, as well as via an acquisition facility from the company's banking consortium, led by NordLB.

PharmaLex expects the acquisition to increase its presence in the UK market.

Auctus acquired a 50.1% stake in PharmaLex in October 2014, when the company was known as Yes Pharma Services. PharmaLex generated revenues of €15m and employed 150 people at the time of the investment.

Auctus invested in PharmaLex via Auctus III, which held a final close in April 2011 on €155m. The fund deployed tickets of €5-15m, focusing on DACH businesses with revenues of €10-100m.

The company has made a number of bolt-ons during the investment period. In 2015, PharmaLex bolted on pharmaceutical consultancies ActioMed and Wainwright. In March 2016, PharmaLex acquired Norway-based drug development consultancy Lindeq. In February 2020, PharmaLex bought US-based Arbour Group from Keystone Capital.

PharmaLex now has 1,000 employees and expects to generate revenues of more than €120m in 2020.

Company
Founded in 2001, Regulis provides pharmaceutical consulting services in regulation, pharmacovigilance and quality assurance. It covers processes including product development, registration, licensing applications and maintenance, as well as dossier publications. The company is based in Tring, in Hertfordshire. It generates revenues of less than €5m and has 20 employees.

People
Auctus Capital Partners – Benjamin Seifert (investment director).
PharmaLex – Thomas Dobmeyer (CEO); Jon Jeffery (head of UK/Ireland, managing director).
Regulis Consulting – Kim Wharton (founder, managing director).

Advisers
Vendor – Consulting M&A (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Healthcare
• Build-up
• Acquisition finance
• Germany
• AUCTUS Management GmbH & Co KG